News

The median progression-free survival among patients in the intention-to-treat population who received niraparib was 24.8 months compared with 8.3 months among patients who received placebo.

What happens when there is a shortage of chemotherapy drugs? How will this affect patients?

Linda Bloom, MPA, RN, OCN, explains how amplifiers and audio interpreter tablets can be vital resources during cancer care.

Each month, Oncology Nursing News® takes a look back at our most popular stories.

It is essential to continue to develop and incorporate educational strategies to increase screening for colorectal cancer in our communities.

Effective interventions exist for cancer-related sexual dysfunction, but higher-quality research is still needed to optimize management.

Black patients with multiple myeloma may be at a higher-risk for bortezomib-induced peripheral neuropathy compared with non-Black patients.

The FDA has approved luspatercept to treat anemia in patients with lower-risk myelodysplastic syndromes.

Jennifer Cargile, MEd, CCC-SLP, shares some examples of how she helped patients continue their daily activities while they experienced symptoms of cancer-related cognitive impairment.

The program’s initiative aims to identify those at increased risk for cancer through assessment and testing and then formulate a personalized evidence-based cancer surveillance or screening plan.

Cabozantinib and atezolizumab led to a statistically significant progression-free survival improvement in patients with metastatic castration-resistant prostate cancer and measurable soft tissue disease.

Selpercatinib led to improved progression-free survival in patients with advanced or metastatic RET-mutant medullary thyroid cancer.

The FDA has granted enzalutamide priority review designation based on data from the phase 3 EMBARK trial.

A retrospective study highlights the need to examine sustainable reimbursement structures for telehealth services.

It is anticipated that health care spending will grow by an annual average of 5.4% over the next 8 years.

Among patients with symptomatic Waldenström macroglobulinemia, the very good partial response rate with zanubrutinib was 36.3% vs 25.3% with ibrutinib.

At 85.3 months follow-up, the median overall survival with pembrolizumab was 32.7 months vs 15.9 months with ipilimumab.

Tetyana Furmanets, CRNP, MSN, discusses the tools she uses to help patients navigate myeloproliferative neoplasm symptom management.

Oncology nurses can help patients with metastatic lung cancer find meaning in their experiences and potentially help them cope more effectively with their diagnosis.

Experts with the Society for Integrative Oncology and the American Society of Clinical Oncology recommend mindfulness-based interventions to help patients with cancer manage anxiety and depression symptoms.

As we continue to slowly recover from the trauma of the COVID-19 pandemic, we are facing a new problem: chemotherapy shortages.

The FDA has granted ivosidenib priority review designation based on data from a phase 1 trial.

At median follow up of 33.6 months, patients who received the triplet combination of tucatinib, letrozole, and palbociclib, experienced a median progression-free survival of 8.4 months.

FoundationOne CDx is a next-generation sequencing–based in vitro diagnostic device developed to detect substitutions, insertion, and deletion alterations using 1 tissue sample.

Jennifer Cargile, MEd, CCC-SLP, shares some signs and symptoms of cancer-related cognitive impairment that the oncology nurse should be looking out for.

ASCO has updated its recommendations for systemic therapies in melanoma.

Florida Cancer Specialists & Research Institute has experts who administer the latest and most advanced treatments for cancer available within the communities where their patients live.

Oncology nurses across the country are spearheading initiatives to improve education, attitudes, and access surrounding palliative care.

Circulating tumor DNA analysis is playing an increasingly important role in colorectal cancer treatment decision-making.